Corrigendum to "Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors" [Cancer Treatm. Rev. 74 (2019) 21-28].

(1)

Contents lists available at

ScienceDirect

Cancer Treatment Reviews

journal homepage:

www.elsevier.com/locate/ctrv

Corrigendum to

“Drug-drug interactions in breast cancer patients treated

with CDK4/6 inhibitors

” [Cancer Treatm. Rev. 74 (2019) 21–28]

Stefano Fogli

a,⁎

, Marzia Del Re

a

, Giuseppe Curigliano

b,c

, Ron H. van Schaik

d

, Patrizio Lancellotti

e

,

Romano Danesi

a

a_{Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy}

b_{Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy} c_{Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy}

d_{European Institute of Oncology IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy} e_{Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands}

The authors regret an oversight regarding the aﬃliations. They

should have been as stated above.

The authors would like to apologise for any inconvenience caused.

https://doi.org/10.1016/j.ctrv.2019.101913

DOI of original article: https://doi.org/10.1016/j.ctrv.2019.01.006

⁎_{Corresponding author at: Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, 55, Via}

Roma, 56126 Pisa, Italy.

E-mail address:stefano.fogli@unipi.it(S. Fogli).

Cancer Treatment Reviews 81 (2019) 101913